Vor Biopharma Inc.
NASDAQ: VOR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jean-Paul Kress
- Employees
- 159
- Headquarters
- Cambridge, United States
- IPO year
- 2021
- Market cap
- $99.2M
- Website
- https://www.vorbio.com
Loading VOR…
Loading profile data…Frequently asked questions about VOR
What does Vor Biopharma Inc. (VOR) do?
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and vario...
Where does VOR trade?
Vor Biopharma Inc. (VOR) trades on the NASDAQ Global Select.
What sector is VOR in?
Vor Biopharma Inc. (VOR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vor Biopharma Inc.?
Jean-Paul Kress is the chief executive officer of Vor Biopharma Inc. (VOR).
Where is Vor Biopharma Inc. headquartered?
Vor Biopharma Inc. is headquartered in United States.
Does VOR pay a dividend?
Vor Biopharma Inc. (VOR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VOR go public?
Vor Biopharma Inc. (VOR) completed its initial public offering in 2021.